ArticleScientific reports2025
Dual antibiotic PLGA microspheres for the treatment of traumatic osteomyelitis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research progress of 3D-printed anti-infective bone tissue engineering scaffolds based on triply periodic minimal surface structures.APL bioengineering · 2026Review
- Context-dependent roles of the NLRP3 inflammasome in osteomyelitis and strategies for precision modulation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic osteomyelitis (TO) treatment remains challenging due to biofilm formation and poor antibiotic penetration. We developed poly(lactic-co-glycolic acid) (PLGA) microspheres co-loaded with moxifloxacin/rifampicin (M/R-P) to address these limitations. Key findings: In vitro: The microspheres showed (1) no cytotoxicity (CCK-8 assay; live/dead staining; cytoskeletal staining; SEM visualization), and (2) no inhibition of osteogenic potential (ALP activity).In vivo: M/R-P microspheres significantly reduced MRSA burden ( 8 ± 3 × 10³ CFU/g) compared to debridement-only controls (3143 ± 727 × 10³ CFU/g; p < 0.0001), and near-complete infection resolution (histopathology). Conclusion: These results demonstrate that the M/R-P microspheres possess excellent safety profiles, favorable cytocompatibility, and remarkable antibacterial efficacy. The findings confirm the feasibility of our innovative approach using PLGA as a drug delivery carrier for localized antibiotic therapy in chronic osteomyelitis treatment, achieved through technological optimization for combined antibiotic administration. This provides a novel strategic direction for ultimately overcoming the clinical challenge of traumatic osteomyelitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.